Quick Answer
PROKIDNEY CORP. reported Research And Development Expense of $114.12 million for the year ending 2025.
- PROKIDNEY CORP. showed a decrease of -10.6% in Research And Development Expense from 2024 to 2025.
- This data is from PROKIDNEY CORP.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $14.74 million | Q1 2022: $28.49 million | Q2 2022: $11.56 million | Q3 2022: $21.13 million | Q1 2023: $25.62 million | Q2 2023: $26.36 million | Q3 2023: $32.20 million | Q1 2024: $27.23 million | Q2 2024: $29.40 million | Q3 2024: $31.25 million | Q1 2025: $27.26 million | Q2 2025: $25.88 million | Q3 2025: $26.82 million.
- Over the full 6 years of available data (2020 to 2025), PROKIDNEY CORP.'s Research And Development Expense has grown by 442.4%.
- Historical annual values: Fiscal year 2025: $114.12 million | Fiscal year 2024: $127.67 million | Fiscal year 2023: $106.71 million | Fiscal year 2022: $82.07 million | Fiscal year 2021: $46.26 million | Fiscal year 2020: $21.04 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: